Thus, the ability of RT to stimulate both local and systemic antitumor immune response can be amplified when combined with ICIs such as anti-programmed cell death protein 1 (anti-PD-1 or α-PD-1), demonstrating its promise in cancer immunotherapy [110,111]. The gene discussed is PDCD1; the disease is cancer.